Van­da's gas­tric drug flops in late-stage test, crash­ing the biotech's stock

You may re­mem­ber Van­da Phar­ma­ceu­ti­cals from its brief feud with the FDA over a par­tial clin­i­cal hold on gas­tric drug tradip­i­tant — a fight it would lose in court a cou­ple years ago. Now, that same drug is in hot wa­ter af­ter fail­ing a piv­otal test.

Tradip­i­tant, an in-li­censed drug from Eli Lil­ly be­ing test­ed in gas­tro­pare­sis, flopped a Phase III study look­ing to re­duce nau­sea symp­toms against place­bo, the biotech said Fri­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER